Boehring Ingelheim Pharmaceuticals will pay $95 million to settle allegations that it promoted three of its drugs for uses that were not approved by the Food and Drug Administration (FDA). The three drugs are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent, and the hypertension drug Micardis. The Justice Department also said Boehring Ingelheim promoted the use of the chronic obstructive pulmonary disease drug Atrovent at doses higher than what was approved by drug regulators. The settlement with Boehring Ingelheim also resolved allegations that the drug company paid kickbacks to health care professionals to entice them to ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.